IN2012DN04908A - - Google Patents

Download PDF

Info

Publication number
IN2012DN04908A
IN2012DN04908A IN4908DEN2012A IN2012DN04908A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A IN 4908DEN2012 A IN4908DEN2012 A IN 4908DEN2012A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A
Authority
IN
India
Prior art keywords
antibody
disclosed
antibodies
expressing cells
drug conjugates
Prior art date
Application number
Other languages
English (en)
Inventor
Michel Pierres
Eric Vivier
Myriam Baratin
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43827827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN04908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of IN2012DN04908A publication Critical patent/IN2012DN04908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN4908DEN2012 2009-12-09 2010-12-08 IN2012DN04908A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28501809P 2009-12-09 2009-12-09
PCT/IB2010/003411 WO2011070443A1 (fr) 2009-12-09 2010-12-08 Anticorps monoclonaux qui se lient à b7h6 et leurs utilisations

Publications (1)

Publication Number Publication Date
IN2012DN04908A true IN2012DN04908A (fr) 2015-09-25

Family

ID=43827827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4908DEN2012 IN2012DN04908A (fr) 2009-12-09 2010-12-08

Country Status (18)

Country Link
US (2) US8822652B2 (fr)
EP (1) EP2510011B2 (fr)
JP (2) JP2013513380A (fr)
CN (2) CN104926942B (fr)
BR (1) BR112012013975B8 (fr)
CA (1) CA2783740C (fr)
DK (1) DK2510011T3 (fr)
EA (1) EA024629B1 (fr)
ES (1) ES2523472T3 (fr)
HR (1) HRP20141170T1 (fr)
IN (1) IN2012DN04908A (fr)
MX (1) MX2012006443A (fr)
PL (1) PL2510011T3 (fr)
PT (1) PT2510011E (fr)
RS (1) RS53667B1 (fr)
SI (1) SI2510011T1 (fr)
SM (1) SMT201400184B (fr)
WO (1) WO2011070443A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011059836A2 (fr) 2009-10-29 2011-05-19 Trustees Of Dartmouth College Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
EA024629B1 (ru) 2009-12-09 2016-10-31 Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль Моноклональные антитела, связывающие b7h6, и их применение
WO2013033626A2 (fr) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Produits thérapeutiques ciblant un récepteur nkp30
WO2013037727A1 (fr) * 2011-09-13 2013-03-21 Deutsches Krebsforschungszentrum Anticorps monoclonal thérapeutiquement actif contre le polypeptide b7-h6
WO2013169691A1 (fr) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anticorps anti-b7-h6, protéines de fusion, et leurs procédés d'utilisation
WO2014044799A1 (fr) * 2012-09-21 2014-03-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et trousses pour le diagnostic d'états inflammatoires impliquant la détection, l'identification ou l'estimation de polypeptides b7-h6 solubles
EP2711707A1 (fr) 2012-09-21 2014-03-26 Institut Gustave Roussy Procédés et kits pour prédire la sensibilité d'un sujet à une chimiothérapie
WO2017181001A1 (fr) * 2016-04-15 2017-10-19 Trustees Of Dartmouth College Anticorps b7-h6 à haute affinité et fragments d'anticorps
WO2017214433A1 (fr) * 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinaisons de conjugués anticorps-médicament à base de pbd avec des d'inhibiteurs de flt3
WO2019099687A1 (fr) * 2017-11-16 2019-05-23 Antigenesis Llc Systèmes et procédés de mort cellulaire immunogène induite par lysosome
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
CA3105448A1 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molecules d'anticorps anti-tcr et leurs utilisations
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3164182A1 (fr) * 2020-01-17 2021-07-22 Liu XUE Anticorps anti-nkp30 et methode d'utilisation
WO2022200525A1 (fr) 2021-03-26 2022-09-29 Innate Pharma Protéines multi-spécifiques comprenant un site de liaison à nkp46, un site de liaison à un antigène tumoral fusionné à une cytokine pour la liaison à des cellules nk
WO2022258678A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkp30, un récepteur de cytokine, un antigène tumoral et cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (fr) 2021-06-09 2022-12-15 Innate Pharma Protéines multispécifiques se liant à nkg2d, récepteur de cytokine, antigène tumoral et cd16a
CN114395043B (zh) * 2021-12-07 2023-07-11 合肥天港免疫药物有限公司 Ncr3lg1抗体及其应用
CN114395045B (zh) * 2021-12-07 2023-06-09 合肥天港免疫药物有限公司 B7h6抗体及其应用
CN114395047B (zh) * 2021-12-07 2023-11-07 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395044B (zh) * 2021-12-07 2023-12-29 合肥天港免疫药物有限公司 重组抗体及其应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
WO2024005422A1 (fr) * 2022-06-29 2024-01-04 고려대학교 산학협력단 Variants de b7-h6 à affinité de liaison améliorée pour nkp30
JP2025537792A (ja) * 2022-11-16 2025-11-20 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 疾患治療での使用のためのｔ細胞－ｎｋ細胞相互作用阻害剤
WO2024208818A1 (fr) 2023-04-04 2024-10-10 Innate Pharma Récepteur antigénique chimérique modulaire

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4883662A (en) 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5082833A (en) 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
WO1998036765A1 (fr) 1997-02-25 1998-08-27 Arizona Board Of Regents Isolement et analyse de la structure des depsipeptides cytostatiques lineaires et des cyclo-depsipeptides cytostatiques dolastatine 16, dolastatine 17, dolastatine 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2769101A (en) * 2000-01-07 2001-07-24 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
AU2003258714A1 (en) * 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
AU2006247592A1 (en) * 2005-05-12 2006-11-23 Zymogenetics, Inc. Methods of using pNKp30, a member of the B7 family, to modulate the immune system
EP2144930A1 (fr) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
CN102099055A (zh) 2007-10-04 2011-06-15 津莫吉尼蒂克斯公司 B7家族成员zB7H6及相关的组合物和方法
EA024629B1 (ru) 2009-12-09 2016-10-31 Институт Насьональ Де Ла Сант Де Ла Решерше Медикаль Моноклональные антитела, связывающие b7h6, и их применение

Also Published As

Publication number Publication date
US20130004432A1 (en) 2013-01-03
US9663577B2 (en) 2017-05-30
EA024629B1 (ru) 2016-10-31
BR112012013975A2 (pt) 2017-01-10
JP2017031147A (ja) 2017-02-09
JP6212181B2 (ja) 2017-10-11
HRP20141170T1 (hr) 2015-01-30
MX2012006443A (es) 2012-06-28
PL2510011T3 (pl) 2015-02-27
US8822652B2 (en) 2014-09-02
DK2510011T3 (en) 2014-12-01
BR112012013975B8 (pt) 2021-05-25
CN102741290A (zh) 2012-10-17
SI2510011T1 (sl) 2014-12-31
US20150056214A1 (en) 2015-02-26
PT2510011E (pt) 2014-12-12
ES2523472T3 (es) 2014-11-26
JP2013513380A (ja) 2013-04-22
WO2011070443A1 (fr) 2011-06-16
EA201270654A1 (ru) 2013-02-28
CN104926942A (zh) 2015-09-23
SMT201400184B (it) 2015-01-15
CA2783740C (fr) 2020-03-10
CN102741290B (zh) 2015-04-22
BR112012013975B1 (pt) 2021-01-12
EP2510011A1 (fr) 2012-10-17
RS53667B1 (sr) 2015-04-30
EP2510011B1 (fr) 2014-09-17
EP2510011B2 (fr) 2021-03-31
CA2783740A1 (fr) 2011-06-16
CN104926942B (zh) 2018-09-14

Similar Documents

Publication Publication Date Title
IN2012DN04908A (fr)
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
NO20084356L (no) Anti TAT226-antistoffer og immunokonjugater
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
MY170719A (en) Antibody-drug conjugates
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2009014708A3 (fr) Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
EP2225277A4 (fr) Anticorps dirigés contre un épitope associé au cancer de variant de nfkbib et ses utilisations
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
NZ610976A (en) Anti-mesothelin antibodies and immunoconjugates
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
NZ616382A (en) Antibodies specific to cadherin-17
WO2009046407A3 (fr) Zb7h6 membre de la famille b7 et compositions et procédés apparentés
MY197840A (en) Cross-linkers and their uses
IL218740A0 (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
IL214983A0 (en) Antibody drug conjugated that bind monomethyl auristatin e (mmae), compositions comprisimg the same and uses thereof
MX2010007767A (es) Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
AU2011343161A8 (en) Human anti-SOD1 antibodies
AU2012335543A8 (en) HER3 antibodies and uses thereof
EP2233501A4 (fr) Anticorps monoclonal anti-cd34 humanisé, sa préparation et ses utilisations
MX375079B (es) ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
EP2322562A4 (fr) Anticorps monoclonal et immunodosage l'utilisant
EP2519542A4 (fr) Anticorps anti-cdh3 et utilisations de ceux-ci